cardiac med

 

HF Դ ŸĿ(link)

CCB(link)

̳õ

 

50kg ( 500 ͽ) : 1mcg/kg/min =3mg/hr    500/mg x 3 cc/hr= (ְ mcg) x 1500/ mds

           1000 ͽ : (ְ mcg) x 3000/ mds

 

: ۿ

concor, atacand post MI , HF ȯڿ molsiton d/c

 

Ÿ ( Ȯ ȿ ) : Ȯȿ ϰ л(л Ĺκ ϴ, ٰ µ), tachycardia ȿ´

l  250mg(1A) , 500cc ͽ , 20cc/hr 50kgȯڿ ָ  -> 3.3ug / kg/ min

l  Ÿ ( 3-15 ug/kg/min)

l  200 ug/kg/min ϰ ɼ ִ(ȯ ġ)

l  ȯ

l  ִ 2A 500mix 40cc/hr(15ug/kg/min) ִġ

b1 ۿ , ̾ b2ۿ(Ȯ) ɹⷮ, ɹڵ ϰų (CO reflex bradycardia) CO , SVRҷ MAP , ۿ: VPC, tachycardia (ȯ ġ)

½ɽ =PCWP (ȯ ġ)= δ()

refractory heart failure , cardiogenic shock (ȯ ġ)

Ÿο ڱ ۾ Ű, ɱ ҼҸ Ų. ɺ ̹ ۾ 䱸 ִȭ Ǿ־ ɺȯڿ طο ִ.(ȯ ġ)

=> õõ Ѿ ޽ heart failure ް ִ ȯڰ dz ִ.(¥ PO )()

 

Vassopressor °? SBP base 30mmHg, MAP< 60϶

chronotrope, inotroph coronary vasodilation Ų. inotrope effect myocardial oxygen demend vasodilation ä . daily inotrophԴ occult ischemia ־ daily electrocardiogram screening ʿ ִ.(uptodate)

Excessive vasoconstriction ø⵵ , extremeties inadequate perfusion ų ִ. CO ʰ, volume ¿ SVR 1300dynes x sec/cm5 ߻Ҽ ִ.(uptodate)

 

ۿ : Cardiovascular: Increased heart rate, increased blood pressure, increased ventricular ectopic activity, hypotension, premature ventricular beats (5%, dose related), anginal pain (1% to 3%), nonspecific chest pain (1% to 3%), palpitation (1% to 3%)(uptodate19.3 dobutamine)

    -> ɰѰ δ.()

 

Ĺ ɽǼຸٴ ø(Ÿ ϴ) , tachycardia ü ִ. , ڴٷ (1A 500cc ͽؼ 20mds start)

l  400mg(1A) 500cc ͽ , 20cc/hr 50kg ȯ -> 5.3ug / kg/ min ̿뷮 2 ̻ ٰ

l  Ĺ   1~2ug/kg/min : ַ D1 receptor : renal, mesenteric, cerebral, coronary ۿϿ (uptodate)

                   2~5ug/kg/min : b1 STROKE VOL, b2 Ȯ ణ , a1 SVR : net effect : ణ л(uptodate)

                   5-10ug/kg/min : b1 receptor ۿ(ַ STROKE VOL, VARIABLE HR) (uptodate)

>10ug/kg/min : ַ a receptor ȿ (uptodate)

 

20ug/kg/min Ѿ л¿ ̵ .(uptodate 19.3 dopamine)

20~30ug/kg/min̻ direct vasodilator(epinephrine, norepinephrine) غƶ(uptodate 19.3 dopamine)

 

l  ۿ (uptodate 19.3 dopamine)

         Freqeunt

              Cardiovascular: Ectopic beats, tachycardia, anginal pain, palpitation, hypotension, vasoconstriction (uptodate 19.3 dopamine)

              Headache , Nausea and vomiting , Dyspnea (uptodate 19.3 dopamine)

         Infrequent:

              Cardiovascular: Aberrant conduction, bradycardia, widened QRS complex, ventricular arrhythmia (high dose), gangrene (high dose), hypertension (uptodate 19.3 dopamine)

              Anxiety , Piloerection, serum glucose increased (usually not above normal limits) ,Ⱦл, Ȯ. Azotemia, polyuria(uptodate 19.3 dopamine)

 

Esmolol( 100mg)

 

(AF RVR) : ó 25mg (1а) -> ٷ ̾ 10mg 4а -> ȿ -> 25mg 1а -> 20mg 4а -> ȿ -> 25mg 1а -> 30mg 4а -> 25mg 1а -> 40mg 4а(ִ 60mg )

 

ƹ̿ٷ150mg/1A

 

ȭ: 5mg/kg ֻ 250ml Ͽ 20-2ð

60kg 2A 250cc ͽϿ 125cc/hr - 750cc/hr ӵ

24ð 2-3ȸ ݺ .

 

: 10-20mg/kg ֻ 250ml Ͽ 2-3ϰ. 1 600-800mg, 1 ִ 1200mg. ֻ 1°, (1 600mg) ġȯŰ 1 800-1000mg

4A(600mg)-8A(1200mg) 250cc mix Ͽ 5cc/hr(2) - 3.3cc/hr(3)

׷鼭 뷮 ¿ 汸 ġȯ (ڴٷ 200mg 1T tid)

 

ȯ ġ : ʱ 300mg IV (̰ )  ι° 150mg IV :  ɽǼ , 浿 ɽǺƿ ȴ, а Ҽ ִ(ȯ ġ)

 

 

븣dz(septic shock ַ, cardiogenic shock ¾)  븣Ƶ巹 0.1% 10ml( norepinephrine bitartrate 20/10)

a1 vasoconstriction  > b1 chronotrophic effect a1 vasoconstriction reflex bradycardia HR ״ Ȥ , CO , SVR(uptodate) MAP

ҽŰ, septic shock ҳ ջ߾Ѵ(ȯ ġ)

  -
-
ʱ 8-12 mcg/min ֻ, , 2-4 mcg/min ֻ, 68 mg/day //⼭ 뷮 дkg ƴ϶ д// ( 20mg 500 ͽϸ 40ug/mL )

- ʱ 0.5-1 mcg/min ֻ, ġ ʴ ũ ȯڴ 8-30 mcg/min

 septic shock ġ뷮 0.2~1.3ug/kg/min :  5%500 2A(40mg) mixϸ 1mcg/min ַϸ 37.5mds(ȯ ġ)

 

 ACLS dosing range : 0.1-0.5 mcg/kg/minute (6-30 mcg/minute in a 60 kg patient)(uptodate19.3 norepinephrine AHA2010)

ۿ: Cardiovascular: Arrhythmias, bradycardia, peripheral (digital) ischemia(uptodate 19.3 norepinephrine)

 

Ÿ : CO (, HR״) / : , CO (HR ״)

 

 

dz b1 >> b2<->a1 : CO SVR , ҿ ȿ , a1>b1,b2 SVR CO(uptodate)

            anaphylacis , septic shock 2(uptodate)

 

NTG (ȿ ſ ӽð ª)(ȯ ġ)

< 40ug/min : Ȯȿ : ɹⷮ ָ鼭 (߽ƾ, PCWP) ҽŴ(ȯ ġ)

߰뷮 40~200ug/min : ư ȥ Ȯȿ : Ȯ(SVR) ɹⷮ ϱ (ȯ ġ)

> 200ug/min : Ȯȿ 켼 : ⼭ʹ (ȯ ġ)

  1. Ʈα۸

  2. Ʈõ : Ȯȿ Ʈα۸ ϴ. Ȯȿ Ʈα۸ ϴ , ﰢ̰ ȿӽð ª(ȯ ġ)

     50mg 5%DW 500 mixϿ (ȯ ġ) 3) : 0.5-10 mcg/kg/.( 1mcg/kg/ شٸ , 3000mcg/hr= 3mg/hr ,50mg 500cc ͽϸ 1mg=10cc 30cc/hr=30mds)(ǰ)

 

߾Ⱦ (¾)

 

ҿ : Pure A agonist : ȿ . SVR Ѵ. neurologic disorder, anathesia induced hypotension , hyperdynamic sepsis . ๰ ƴϴ. SVR1200 (uptodate)

 

Ephedrine dz potency , 븣dz к ڱϸ鼭 ȿ Ÿ post anesthesia induced hypotension (uptodate)

 

Isoproterenol(Isuprel) b1(ino, chrono) HR , b2 ۿ ؼ MAP ϰ, bradycardia induced hypotension (uptodate) ? ̹ ؼ vasodilation , bradycardia ִ ִ()

 

Vasopressin (diabetes inspidus , variceal bleeding ) adrenergic mechanism ƴϰ vasoconstriction , inotrophy Ѵ(uptodate)

 refractory septic shock(2nd agent), refractory anaphylacsis(uptodate)

 

PDE inhibitor

milrinone , inamrinone : inotropic, vasodilatory action Ÿΰ , dysrhythmia . medically refractive heart failure δ,  hypotension . (uptodate)

 

------------------------------------------------------------------------------------------------------------------------------------

sepsis hypotension , fluidְ Ĺ ޾Ҵµ, tachycardia ڴٷ ش. ڴٷ 2 ϵ ִ° ü ִ.

PSVT : ڸ PO ֱ⵵Ѵ

 

Tachycardia control : Ƹٷ, ڸ

 

 

Ⱓ ȯڵ鿡 ϴ ๰

   IV Ĺ

   ī(denopamine : selective b-1 agonist) : Դ Ĺ(Ÿ ´µ)̶ ϸ ȴ. , ɺ ϶ . (R3)

   Ÿ ۿ ϴ. Ÿ IVۿ , ̰ PO̴. ɹڼ п ġ ʴ 汸 (۸), congestive heart failure , pulmonary edema δ(wikipedia)

   ᱹ ɺ ƴ ȯڴ IV Ĺ ۿ . (R3 ׷ ƴѵ)

 

ɺȯ ๰

  ī, , lasix , b-blocker() : װ (R3)

 

 

ACEI(Űǵ)

ۿ : , capacityø , cardiac output, stroke work, and volume Ŵ(venous return پ ϱ? ) (Űǵ)

        , natriuresis (excretion of sodium in the urine). (Űǵ)

        Renin. Angiotensin Angiotensin II and Aldosterone . Bradykinin . (Űǵ)

 

 

 

ñ׸Ʈ(nicorandil)

  BP , ߻Ҽ ִ(Ӹ blood flow) ()